Tall cell papillary thyroid carcinoma: New diagnostic criteria and mutations in BRAF and TERT

Endocrine-Related Cancer

Volumn 22, Issue 3, 2015, Pages 419-429

  Dettmer, Matthias S ^a   Schmitt, Anja ^a   Steinert, Hans ^b   Capper, David ^c   Moch, Holger ^b   Komminoth, Paul ^d   Perren, Aurel ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d TRIEMLI HOSPITAL   (Switzerland)

Author keywords

BRAF; Diagnostic criteria; Papillary thyroid carcinoma; Prognosis; Tall cell; TERT

Indexed keywords

B RAF KINASE; TELOMERASE REVERSE TRANSCRIPTASE; BRAF PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CELL STRUCTURE; CELLULAR DISTRIBUTION; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; KRUSKAL WALLIS TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PAPILLARY THYROID CARCINOMA CELL; PROGNOSTIC ASSESSMENT; PROMOTER REGION; PYROSEQUENCING; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; TALL CELL PAPILLARY THYROID CARCINOMA; THYROID CARCINOMA; CARCINOMA; ENZYMOLOGY; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; THYROID TUMOR; TREATMENT OUTCOME;

CARCINOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; TELOMERASE; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84937030233     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-15-0057     Document Type: Article

References (40)

1. Akslen LA & LiVolsi VA 2000 Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. Cancer 88 1902-1908. (doi:10.1002/(SICI)1097-0142(20000415)88:8〈1902::AID-CNCR20O3.0.CO〉2-Y)
2. Baloch ZW & LiVolsi VA 2006 Microcarcinoma of the thyroid. Advances in Anatomic Pathology 13 69-75. (doi:10.1097/01.pap.0000213006.10362.17)
3. BarbaroD, Incensati RM, Materazzi G, Boni G, Grosso M, Panicucci E, Lapi P, Pasquini C & Miccoli P 2014 The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis. Endocrine 45 462-468. (doi:10.1007/s12020-013-0029-5)
4. Beninato T, Scognamiglio T, Kleiman DA, Uccelli A, Vaca D, Fahey TJ III & Zarnegar R 2013 Ten percent tall cells confer the aggressive features of the tall cell variant of papillary thyroid carcinoma. Surgery 154 1331-1336; discussion 1336. (doi:10.1016/j.surg.2013.05.009)
5. Boos LA, Dettmer M, Schmitt A, Rudolph T, Steinert H, Moch H, Sobrinho-Simoes M, Komminoth P & Perren A 2013 Diagnostic and prognostic implications of the PAX8-PPARg translocation in thyroid carcinomas-a TMA-based study of 226 cases. Histopathology 63 234-241. (doi:10.1111/his.12150)
6. Cancer Genome Atlas Research N 2014 Integrated genomic characterization of papillary thyroid carcinoma. Cell 159 676-690. (doi:10.1016/j.cell.2014.09.050)
7. Cheng S, Serra S, Mercado M, Ezzat S & Asa SL 2011 A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. Clinical Cancer Research 15 2385-2394. (doi:10.1158/1078-0432.CCR-10-2837)
8. DeLellis R, Lloyd R, Heitz P & Eng C. 2004 World Health Organization classification of tumours. In Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press.
9. Dettmer M, Schmitt A, Steinert H, Haldemann A, Meili A, Moch H, Komminoth P & Perren A 2011 Poorly differentiated thyroid carcinomas: how much poorly differentiated is needed? American Journal of Surgical Pathology 35 1866-1872. (doi:10.1097/PAS.0b013e31822cf962)
10. Dettmer M, Schmitt A, Steinert H, Moch H, Komminoth P & Perren A 2012 Poorly differentiated oncocytic thyroid carcinoma-diagnostic implications and outcome. Histopathology 60 1045-1051. (doi:10.1111/j.1365-2559.2012.04188.x)
11. Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C et al. 2012 The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. Journal of Clinical Endocrinology and Metabolism 97 4390-4398. (doi:10.1210/jc.2012-1775)
12. Eloy C, Santos J, Soares P & Sobrinho-Simoes M 2011 The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Archiv 459 265-276. (doi:10.1007/s00428-011-1133-7)
13. Ganly I, Ibrahimpasic T, Rivera M, Nixon I, Palmer FL, Patel SG, Tuttle RMM, Shah JP & Ghossein RM 2013 Prognostic Implications of papillary thyroid carcinoma with tall cell features. Thyroid 24 662-670. (doi:10.1089/thy.2013.0503)
14. Ghossein R & Livolsi VA 2008 Papillary thyroid carcinoma tall cell variant. Thyroid 18 1179-1181. (doi:10.1089/thy.2008.0164)
15. Guerra A, Sapio MR, Marotta V, Campanile E, Rossi S, Forno I, Fugazzola L, Budillon A, Moccia T, Fenzi G et al. 2012a The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 97 517-524. (doi:10.1210/jc.2011-0618)
16. Guerra A, Fugazzola L, Marotta V, Cirillo M, Rossi S, Cirello V, Forno I, Moccia T, Budillon A & Vitale M 2012b A high percentage of BRAF V600E alleles in papillary thyroid carcinoma predicts a poorer outcome. Journal of Clinical Endocrinology and Metabolism 97 2333-2340. (doi:10.1210/jc.2011-3106)
17. Handkiewicz-Junak D, Czarniecka A & Jarzab B 2010 Molecular prognostic markers in papillary and follicular thyroid cancer: current status and future directions. Molecular and Cellular Endocrinology 322 8-28. (doi:10.1016/j.mce.2010.01.007)
18. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L & Garraway LA 2013 Highly recurrent TERT promoter mutations in human melanoma. Science 339 957-959. (doi:10.1126/science.1229259)
19. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C et al. 2009 BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocrine Journal 56 89-97. (doi:10.1507/endocrj.K08E-208)
20. KimTH, ParkYJ, LimJA, AhnHY, Lee EK, LeeYJ, KimKW, Hahn SK, Youn YK, Kim KH et al. 2012 The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118 1764-1773. (doi:10.1002/cncr.26500)
21. Koperek O, Kornauth C, Capper D, Berghoff AS, Asari R, Niederle B, von Deimling A, Birner P & Preusser M 2012 Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. American Journal of Surgical Pathology 36 844-850. (doi:10.1097/PAS.0b013e318246b527)
22. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA & Fagin JA 2013 Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. Journal of Clinical Endocrinology and Metabolism 98 E1562-E1566. (doi:10.1210/jc.2013-2383)
23. Li C, Lee KC, Schneider EB & ZeigerMA 2012 BRAF V600E mutation and Its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. Journal of Clinical Endocrinology 97 4559-4970. (doi:10.1210/jc.2012-2104)
24. Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, Larsson C & Xu D 2013a The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene 33 4978-4984. (doi:10.1038/onc.2013.446)
25. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar A & XingM2013b Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine-Related Cancer 20 603-610. (doi:10.1530/ERC-13-0210)
26. LiVolsi VA 2010 Papillary carcinoma tall cell variant (TCV): a review. Endocrine Pathology 21 12-15. (doi:10.1007/s12022-010-9106-y)
27. Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C et al. 2014 TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 99 E754-E765. (doi:10.1210/jc.2013-3734)
28. Nikiforov YEB, Paul W & Thompson LD 2012 Diagnostic Pathology and Molecular Genetics of the Thyroid: A Comprehensive Guide for Practicing Thyroid Pathology. Baltimore, MD, USA: Lippincott Williams & Wilkins (LWW).
29. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A et al. 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. Journal of Clinical Endocrinology and Metabolism 88 5399-5404. (doi:10.1210/jc.2003-030838)
30. Ostrowski ML & Merino MJ 1996 Tall cell variant of papillary thyroid carcinoma: a reassessment and immunohistochemical study with comparison to the usual type of papillary carcinoma of the thyroid. American Journal of Surgical Pathology 20 964-974. (doi:10.1097/00000478-199608000-00005)
31. Sancisi V, Nicoli D, Ragazzi M, Piana S & Ciarrocchi A 2012 BRAF V600E mutation does not mean distant metastasis in thyroid papillary carcinomas. Journal of Clinical Endocrinology and Metabolism 97 E1745-E1749. (doi:10.1210/jc.2012-1526)
32. Schlumberger MJ 1998 Papillary and follicular thyroid carcinoma. New England Journal of Medicine 338 297-306. (doi:10.1056/NEJM199801293380506)
33. Shimamura M, Nagayama Y, Matsuse M, Yamashita S & Mitsutake N 2014 Analysis of multiple markers for cancer stem-like cells in human thyroid carcinoma cell lines. Endocrine Journal 61 481-490. (doi:10.1507/endocrj.EJ13-0526)
34. Sobin S, Gospodarowicz M & Wittekind C 2009 TNM Classification of Malignant Tumors. 7th Edn. Hoboken, NJ, USA: Wiley-Blackwell.
35. Sobrinho-Simoes M, Sambade C, Nesland JM & Johannessen JV 1989 Tall cell papillary carcinoma. American Journal of Surgical Pathology 13 79-80. (doi:10.1097/00000478-198901000-00014)
36. Statistics Do 2011 Department of Statistics Statistisches Amt des Kantons Zürich. Zürich, Switzerland: Statistisches Amt. (available at: http://www.statistik.zh.ch/internet/justiz-inneres/statistik/de/home.html)
37. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L et al. 2013 Frequency of TERT promoter mutations in human cancers. Nature Communications 4 2185. (doi:10.1038/ncomms3185)
38. Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, Lloyd RV, LiVolsi VA, Papotti M, Sobrinho-Simoes M et al. 2007 Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. American Journal of Surgical Pathology 31 1256-1264. (doi:10.1097/PAS.0b013e3180309e6a)
39. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM et al. 2013 Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. Journal of the American Medical Association 309 1493-1501. (doi:10.1001/jama.2013.3190)
40. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA et al. 2010 Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467 1114-1117. (doi:10.1038/nature09515)